LPS injection dynamically affects BCL6 expression, preferentially in splenic CD8α⁺ cDCs.

<p>C57BL/6 mice were injected with TLR4 agonist LPS by <i>i.p.</i> route. <i>(A)</i> After LPS injection, representative FACS data (n = 4) showing transient segregation of two subpopulations of total cDCs. <i>(B)</i> The average percent ±SEM (n = 4) BCL6^hi in splenic CD11c^hi I-A^int (balck solid bar) or CD11c^int I-A^hi (black open bar) cDCs before and after LPS injection. <i>(C)</i> The average BCL6 MFI ±SEM (n = 4) in splenic CD11c^hi I-A^int (balck solid bar) or CD11c^int I-A^hi (black open bar) cDCs before and after LPS injection. <i>(D)</i> Bar graph showing the average MFI ±SEM (n = 4) of BCL6 in cDC subsets (CD4⁺, CD8α⁺ and CD4⁻CD8α⁻) of total splenic cDCs at 0 h, 2 h, 12 h, 24 h and 72 h after LPS injection. <i>(E)</i> and <i>(F)</i> The average MFI ±SEM (n = 4) of BCL6 in CD4⁺, CD8α⁺ and CD4⁻CD8α⁻ subsets within either CD11c^hi I-A^int<i>(C)</i> or CD11c^int I-A^hi<i>(D)</i> cells at indicated hours after LPS injection. *<i>p</i><0.05; **<i>p</i><0.005; ***<i>p</i><0.001 (two way ANOVA) with multiple comparisons was made between groups <i>(B and C)</i> or within each group compared to values at 0 h <i>(B, C, D, E and F)</i>.